Showing 1 - 13 results of 13 for search 'Geert Jan Groeneveld', query time: 0.09s Refine Results
  1. 1
    Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies

    Analgesic drug development: proof-of-mechanism and proof-of-concept in early phase clinical studies by Hemme J. Hijma, MSc, Geert Jan Groeneveld, MD, PhD

    Published 2021
    Connect to this object online.
    Book
    Save to List
    Saved in:
  2. 2
    A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly selective Nav1.8 inhibitor, in healthy adults

    A phase I, randomized, double‐blind, placebo‐controlled, single‐ and multiple dose escalation study evaluating the safety, pharmacokinetics and pharmacodynamics of VX‐128, a highly... by Hemme J. Hijma, Emilie M. J. vanBrummelen, Pieter S. Siebenga, Geert Jan Groeneveld

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  3. 3
    Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects

    Lack of Detection of the Analgesic Properties of PF‐05089771, a Selective Nav1.7 Inhibitor, Using a Battery of Pain Models in Healthy Subjects by Pieter Siebenga, Guido vanAmerongen, Justin L. Hay, Aoibhinn McDonnell, Donal Gorman, Richard Butt, Geert Jan Groeneveld

    Published 2020
    Connect to this object online.
    Book
    Save to List
    Saved in:
  4. 4
    Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study

    Muscle velocity recovery cycles as pharmacodynamic biomarker: Effects of mexiletine in a randomized double‐blind placebo‐controlled cross‐over study by Titia Q. Ruijs, Ingrid W. Koopmans, Marieke L. deKam, Martijn R. Tannemaat, Geert Jan Groeneveld, Jules A. A. C. Heuberger

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  5. 5
    Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients

    Clinical trial evaluating apomorphine oromucosal solution in Parkinson's disease patients by Eva Thijssen, Bert Tuk, Michel Cakici, Veerle vanVelze, Erica Klaassen, Frans Merkus, Teus vanLaar, Philip Kremer, Geert Jan Groeneveld

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  6. 6
    First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator

    First‐in‐human trial to assess safety, tolerability, pharmacokinetics, and pharmacodynamics of zagociguat (CY6463), a CNS‐penetrant soluble guanylyl cyclase stimulator by Sebastiaan J. W. vanKraaij, Pim Gal, Laura G. J. M. Borghans, Erica S. Klaassen, Francis Dijkstra, Christopher Winrow, Chad Glasser, Geert Jan Groeneveld

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  7. 7
    A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls

    A leucine‐rich repeat kinase 2 (LRRK2) pathway biomarker characterization study in patients with Parkinson's disease with and without LRRK2 mutations and healthy controls by Maurits F. J. M. Vissers, Matthew D. Troyer, Eva Thijssen, Diana R. Pereira, | Jules A. A. C. Heuberger, Geert Jan Groeneveld, Sarah Huntwork‐Rodriguez

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  8. 8
    The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant

    The interactive walkway provides fit‐for‐purpose fall‐risk biomarkers in the elderly: Comparison of zolpidem and suvorexant by Ingrid Koopmans, Daphne Geerse, Lara deRidder, Melvyn Roerdink, Maria Joanna Juachon, Clemens Muehlan, Jasper Dingemanse, Joop vanGerven, Geert Jan Groeneveld, Rob Zuiker

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  9. 9
    Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants

    Randomized, placebo‐controlled study on the effects of intravenous GSK3858279 (anti‐CCL17) on a battery of evoked pain tests in healthy participants by Yvonne Boyle, Hemme J. Hijma, Jamie Rees, Jagtar Nijjar, Eirini Panoilia, Yolanda Alvarez, Sarah Siederer, Emma Greening, Edward Emery, Kathy Abbott Banner, Geert Jan Groeneveld

    Published 2024
    Connect to this object online.
    Book
    Save to List
    Saved in:
  10. 10
    Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis

    Kinetics of myelin breakdown products: A labeling study in patients with progressive multiple sclerosis by Kawita M. S. Kanhai, Sebastiaan C. Goulooze, Jeroen van derGrond, Amy C. Harms, Thomas Hankemeier, Ajay Verma, Gersham Dent, Juan Chavez, Henri Meijering, Geert Jan Groeneveld

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  11. 11
    Acute retigabine‐induced effects on myelinated motor axons in amyotrophic lateral sclerosis

    Acute retigabine‐induced effects on myelinated motor axons in amyotrophic lateral sclerosis by Boudewijn T. H. M. Sleutjes, Diederik J. L. Stikvoort García, Maria O. Kovalchuk, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Hessel Franssen, Leonard H. van denBerg

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:
  12. 12
    Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty

    Mitochondrial function, grip strength, and activity are related to recovery of mobility after a total knee arthroplasty by Marcus P. J. vanDiemen, Dimitrios Ziagkos, Matthijs D. Kruizinga, Menno R. Bénard, Philip Lambrechtse, Joris A. J. Jansen, Barbara A. M. Snoeker, Maaike G. J. Gademan, Adam F. Cohen, Rob G. H. H. Nelissen, Geert Jan Groeneveld

    Published 2023
    Connect to this object online.
    Book
    Save to List
    Saved in:
  13. 13
    Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib studies in healthy subjects and patients

    Safety, pharmacokinetics and target engagement of novel RIPK1 inhibitor SAR443060 (DNL747) for neurodegenerative disorders: Randomized, placebo‐controlled, double‐blind phase I/Ib... by Maurits F. J. M. Vissers, Jules A. A. C. Heuberger, Geert Jan Groeneveld, Jerome Oude Nijhuis, Peter Paul De Deyn, Salah Hadi, Jeffrey Harris, Richard M. Tsai, Andres Cruz‐Herranz, Fen Huang, Vincent Tong, Rebecca Erickson, Yuda Zhu, Kimberly Scearce‐Levie, Jennifer Hsiao‐Nakamoto, Xinyan Tang, Megan Chang, Brian M. Fox, Anthony A. Estrada, Robert J. Pomponio, Miguel Alonso‐Alonso, Moshe Zilberstein, Nazem Atassi, Matthew D. Troyer, Carole Ho

    Published 2022
    Connect to this object online.
    Book
    Save to List
    Saved in:

Search Tools: